

Overview delle principali presentazioni sui farmaci Roche all'ASCO 2017:

Medicine	Abstract title	Abstract number
Pertuzumab <i>(investigational use)</i>	APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC)	Abstract LBA500 (oral) Monday, 5 June 09.45 - 12.45 CDT
Alectinib <i>(investigational use)</i>	Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study	Abstract LBA9008 (oral) Tuesday, 6 June 09.45 - 12.45 CDT
CEA-CD3 TCB (RG7802) <i>(investigational use)</i>	Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC)	Abstract 3002 (oral) Monday, 5 June 13.15 - 16.15 CDT
ipatasertib <i>(investigational use)</i>	LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC)	Abstract 1009 (poster) Sunday, 4 June 16.45 – 18.00 CDT
Atezolizumab <i>(investigational use)</i>	IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun)	Abstract 4505 (oral) Monday, 5 June 08.00 – 10.00 CDT
Atezolizumab <i>(investigational use)</i>	Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study	Abstract 9092 (poster) Saturday, 3 June 08.00 – 11.30 CDT
Atezolizumab <i>(investigational use)</i>	Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC)	Abstract 5585 (poster) Saturday, 3 June 13.15 – 16.45 CDT
Atezolizumab <i>(investigational use)</i>	Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study	Abstract 9001 (oral) Tuesday, 6 June 09.45 – 12.45 CDT
atezolizumab / GDC-0919	A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced	Abstract 105 (oral)

<i>(investigational use)</i>	or metastatic solid tumors	Sunday, 4 June 09.45 – 11.15CDT
------------------------------	----------------------------	------------------------------------